Correction to: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (Journal of Hematology & Oncology, (2024), 17, 1, (128), 10.1186/s13045-024-01636-4)

Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., Khassawna, T. E., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M., & 6 anderenRohnke, M., Wenisch, S., Vanderkerken, K., Hanke, T., Seckinger, A. & Alt, V., 24 jan. 2025, In: Journal of Hematology & Oncology. 18, 1, 1 blz., 11.

Onderzoeksoutput: Comment/debate

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group, Shi, Q., Paiva, B., Pederson, L. D., Dimier, N., Talpes, E., Prior, T. J., Orfao, A., Moreau, P., Sonneveld, P., Kumar, S. K., Dixon, J. G., Patel, R., Bartlett, B. J., Schecter, J., McCarthy, P., Hose, D., Seckinger, A., Mattia, DA., Goldschmidt, H., & 6 anderenOliva, S., Owen, R. G., Anderson, K. C., San-Miguel, J., Durie, B. G. M. & Munshi, N., 10 apr. 2025, In: Journal of Clinical Oncology. 43, 11, blz. 1289-1301 13 blz.

Onderzoeksoutput: Article › peer review

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., El Khassawna, T., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M., & 6 anderenRohnke, M., Wenisch, S., Vanderkerken, K., Hanke, T., Seckinger, A. & Alt, V., 18 dec. 2024, In: Journal of Hematology & Oncology. 17, 1, 20 blz., 128.

Onderzoeksoutput: Article › peer review

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K., & 6 anderenHanoun, C., Schnitzler, P., Klemm, S., Goldschmidt, H., Raab, M. & Elmaagacli, A., dec. 2024, In: Hematology (Amsterdam, Netherlands). 29, 1, 7 blz., 2320006.

Onderzoeksoutput: Article › peer review

Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics

Kuric, M., Beck, S., Schneider, D., Rindt, W., Evers, M., Meißner-Weigl, J., Zeck, S., Krug, M., Herrmann, M., Hartmann, T. N., Leich, E., Rudert, M., Docheva, D., Seckinger, A., Hose, D., Jundt, F. & Ebert, R., 29 apr. 2024, In: Cancer research communications. 4, 4, blz. 1150-1164 15 blz.

Onderzoeksoutput: Article › peer review